Trial Outcomes & Findings for Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors (NCT NCT04079712)
NCT ID: NCT04079712
Last Updated: 2025-12-12
Results Overview
Participants who are considered to have a response are those with either a complete response (CR) (disappearance of all target lesions) or a partial response (PR) (\>=30% decrease in the sum of the longest diameter of target lesions) using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 and assessed by CT or MRI scan.
Recruitment status
ACTIVE_NOT_RECRUITING
Study phase
PHASE2
Target enrollment
17 participants
Primary outcome timeframe
Up to 3.5 years
Results posted on
2025-12-12
Participant Flow
Participant milestones
| Measure |
Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab)
Patients receive cabozantinib s-malate PO QD on days 1-21 of cycles 1-4 and days 1-28 of subsequent cycles, nivolumab IV over 30 minutes on day 1 all cycles, and ipilimumab IV over 90 minutes on day 1 of cycles 1-4 only. Treatment repeats every 21 days for 4 cycles then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
|
|---|---|
|
Overall Study
STARTED
|
17
|
|
Overall Study
COMPLETED
|
16
|
|
Overall Study
NOT COMPLETED
|
1
|
Reasons for withdrawal
| Measure |
Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab)
Patients receive cabozantinib s-malate PO QD on days 1-21 of cycles 1-4 and days 1-28 of subsequent cycles, nivolumab IV over 30 minutes on day 1 all cycles, and ipilimumab IV over 90 minutes on day 1 of cycles 1-4 only. Treatment repeats every 21 days for 4 cycles then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
|
|---|---|
|
Overall Study
Disease progression before starting treatment
|
1
|
Baseline Characteristics
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
Baseline characteristics by cohort
| Measure |
Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab)
n=17 Participants
Patients receive cabozantinib s-malate PO QD on days 1-21 of cycles 1-4 and days 1-28 of subsequent cycles, nivolumab IV over 30 minutes on day 1 all cycles, and ipilimumab IV over 90 minutes on day 1 of cycles 1-4 only. Treatment repeats every 21 days for 4 cycles then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=26 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
9 Participants
n=26 Participants
|
|
Age, Categorical
>=65 years
|
8 Participants
n=26 Participants
|
|
Age, Continuous
|
62 Years
n=26 Participants
|
|
Sex: Female, Male
Female
|
4 Participants
n=26 Participants
|
|
Sex: Female, Male
Male
|
13 Participants
n=26 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=26 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
15 Participants
n=26 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=26 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=26 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=26 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=26 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=26 Participants
|
|
Race (NIH/OMB)
White
|
15 Participants
n=26 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=26 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=26 Participants
|
|
Region of Enrollment
United States
|
17 participants
n=26 Participants
|
|
Weight
|
88 kilogram (kg)
n=26 Participants
|
|
Body Surface Area (BSA)
|
2.0 meters squared (m^2)
n=26 Participants
|
PRIMARY outcome
Timeframe: Up to 3.5 yearsParticipants who are considered to have a response are those with either a complete response (CR) (disappearance of all target lesions) or a partial response (PR) (\>=30% decrease in the sum of the longest diameter of target lesions) using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 and assessed by CT or MRI scan.
Outcome measures
| Measure |
Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab)
n=16 Participants
Patients receive cabozantinib s-malate PO QD on days 1-21 of cycles 1-4 and days 1-28 of subsequent cycles, nivolumab IV over 30 minutes on day 1 all cycles, and ipilimumab IV over 90 minutes on day 1 of cycles 1-4 only. Treatment repeats every 21 days for 4 cycles then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
|
|---|---|
|
Number of Participants With a Response
Response
|
2 Participants
|
|
Number of Participants With a Response
No Response
|
14 Participants
|
SECONDARY outcome
Timeframe: Up to 3.5 yearsProgression is defined as a \>= 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) and assessed by CT or MRI scan. The duration is from the date of registration to the time of progression or death, whichever occurs first.
Outcome measures
| Measure |
Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab)
n=16 Participants
Patients receive cabozantinib s-malate PO QD on days 1-21 of cycles 1-4 and days 1-28 of subsequent cycles, nivolumab IV over 30 minutes on day 1 all cycles, and ipilimumab IV over 90 minutes on day 1 of cycles 1-4 only. Treatment repeats every 21 days for 4 cycles then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
|
|---|---|
|
Progression Free Survival (PFS)
|
85 Days
Interval 23.0 to 902.0
|
SECONDARY outcome
Timeframe: Up to 3.5 yearsAdverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) 5.0 criteria. The population is defined as all patients who have received the study treatment. The highest grade is reported.
Outcome measures
| Measure |
Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab)
n=16 Participants
Patients receive cabozantinib s-malate PO QD on days 1-21 of cycles 1-4 and days 1-28 of subsequent cycles, nivolumab IV over 30 minutes on day 1 all cycles, and ipilimumab IV over 90 minutes on day 1 of cycles 1-4 only. Treatment repeats every 21 days for 4 cycles then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
|
|---|---|
|
Number of Participants Reporting Adverse Events
Grade 5
|
0 Participants
|
|
Number of Participants Reporting Adverse Events
Grade 4
|
3 Participants
|
|
Number of Participants Reporting Adverse Events
Grade 3
|
7 Participants
|
|
Number of Participants Reporting Adverse Events
Grades 1-2
|
6 Participants
|
SECONDARY outcome
Timeframe: Up to 3.5 yearsDCR will be defined as the achievement of Complete Response (CR) (disappearance of all target lesions), Partial Response (PR) (\>=30% decrease in the sum of the longest diameter of target lesions), or Stable Disease (SD) (between \< 30% decrease and \>20% increase in the sum of the longest diameter of target lesions) using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI scan.
Outcome measures
| Measure |
Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab)
n=16 Participants
Patients receive cabozantinib s-malate PO QD on days 1-21 of cycles 1-4 and days 1-28 of subsequent cycles, nivolumab IV over 30 minutes on day 1 all cycles, and ipilimumab IV over 90 minutes on day 1 of cycles 1-4 only. Treatment repeats every 21 days for 4 cycles then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
|
|---|---|
|
Disease Control Rate (DCR)
Achieved disease control
|
9 Participants
|
|
Disease Control Rate (DCR)
Did not achieve disease control
|
7 Participants
|
SECONDARY outcome
Timeframe: Up to 3.5 yearsThe time when measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented.
Outcome measures
| Measure |
Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab)
n=2 Participants
Patients receive cabozantinib s-malate PO QD on days 1-21 of cycles 1-4 and days 1-28 of subsequent cycles, nivolumab IV over 30 minutes on day 1 all cycles, and ipilimumab IV over 90 minutes on day 1 of cycles 1-4 only. Treatment repeats every 21 days for 4 cycles then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
|
|---|---|
|
Duration of Response (DOR)
|
664 Days
Interval 504.0 to 824.0
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Day 35Population: This biomarker assay was not performed as there were insufficient samples available to interpret the planned correlative studies.
Expression of CD8+ T lymphocytes in the tumor tissue at baseline and during treatment.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Day 35Population: This biomarker assay was not performed as there were insufficient samples available to interpret the planned correlative studies.
Presence of myeloid derived suppressor cells in the tumor before and during treatment.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to Day 35Population: This biomarker assay was not performed as there were insufficient samples available to interpret the planned correlative studies.
Presence of tumor-associated macrophages in the tumor at baseline and during treatment.
Outcome measures
Outcome data not reported
Adverse Events
Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab)
Serious events: 10 serious events
Other events: 16 other events
Deaths: 13 deaths
Serious adverse events
| Measure |
Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab)
n=17 participants at risk
Patients receive cabozantinib s-malate PO QD on days 1-21 of cycles 1-4 and days 1-28 of subsequent cycles, nivolumab IV over 30 minutes on day 1 all cycles, and ipilimumab IV over 90 minutes on day 1 of cycles 1-4 only. Treatment repeats every 21 days for 4 cycles then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
|
|---|---|
|
Cardiac disorders
Pericardial effusion
|
5.9%
1/17 • About 3.5 years
|
|
General disorders
Malaise
|
5.9%
1/17 • About 3.5 years
|
|
General disorders
Non-cardiac chest pain
|
5.9%
1/17 • About 3.5 years
|
|
Hepatobiliary disorders
Hepatic failure
|
11.8%
2/17 • About 3.5 years
|
|
Infections and infestations
Appendicitis
|
5.9%
1/17 • About 3.5 years
|
|
Infections and infestations
Cholangitis
|
5.9%
1/17 • About 3.5 years
|
|
Infections and infestations
Sepsis
|
5.9%
1/17 • About 3.5 years
|
|
Infections and infestations
Stoma site infection
|
5.9%
1/17 • About 3.5 years
|
|
Infections and infestations
Tracheitis
|
5.9%
1/17 • About 3.5 years
|
|
Injury, poisoning and procedural complications
Fall
|
5.9%
1/17 • About 3.5 years
|
|
Metabolism and nutrition disorders
Hyponatremia
|
5.9%
1/17 • About 3.5 years
|
|
Musculoskeletal and connective tissue disorders
Generalized muscle weakness
|
5.9%
1/17 • About 3.5 years
|
|
Renal and urinary disorders
Acute kidney injury
|
5.9%
1/17 • About 3.5 years
|
|
Renal and urinary disorders
Urinary retention
|
5.9%
1/17 • About 3.5 years
|
|
Vascular disorders
Hypotension
|
5.9%
1/17 • About 3.5 years
|
|
Vascular disorders
Thromboembolic event
|
5.9%
1/17 • About 3.5 years
|
Other adverse events
| Measure |
Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab)
n=17 participants at risk
Patients receive cabozantinib s-malate PO QD on days 1-21 of cycles 1-4 and days 1-28 of subsequent cycles, nivolumab IV over 30 minutes on day 1 all cycles, and ipilimumab IV over 90 minutes on day 1 of cycles 1-4 only. Treatment repeats every 21 days for 4 cycles then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
|
|---|---|
|
Metabolism and nutrition disorders
Hypophosphatemia
|
41.2%
7/17 • About 3.5 years
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
5.9%
1/17 • About 3.5 years
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
5.9%
1/17 • About 3.5 years
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
17.6%
3/17 • About 3.5 years
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
5.9%
1/17 • About 3.5 years
|
|
Musculoskeletal and connective tissue disorders
Generalized muscle weakness
|
23.5%
4/17 • About 3.5 years
|
|
Musculoskeletal and connective tissue disorders
Muscle cramp
|
17.6%
3/17 • About 3.5 years
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
5.9%
1/17 • About 3.5 years
|
|
Nervous system disorders
Dizziness
|
11.8%
2/17 • About 3.5 years
|
|
Nervous system disorders
Dysgeusia
|
11.8%
2/17 • About 3.5 years
|
|
Nervous system disorders
Headache
|
23.5%
4/17 • About 3.5 years
|
|
Nervous system disorders
Hypersomnia
|
5.9%
1/17 • About 3.5 years
|
|
Nervous system disorders
Peripheral motor neuropathy
|
5.9%
1/17 • About 3.5 years
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
5.9%
1/17 • About 3.5 years
|
|
Nervous system disorders
Presyncope
|
5.9%
1/17 • About 3.5 years
|
|
Psychiatric disorders
Confusion
|
5.9%
1/17 • About 3.5 years
|
|
Psychiatric disorders
Insomnia
|
17.6%
3/17 • About 3.5 years
|
|
Renal and urinary disorders
Dysuria
|
5.9%
1/17 • About 3.5 years
|
|
Renal and urinary disorders
Proteinuria
|
11.8%
2/17 • About 3.5 years
|
|
Reproductive system and breast disorders
Benign Prostatic Hyperplasia
|
5.9%
1/17 • About 3.5 years
|
|
Respiratory, thoracic and mediastinal disorders
Allergic rhinitis
|
11.8%
2/17 • About 3.5 years
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
17.6%
3/17 • About 3.5 years
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
35.3%
6/17 • About 3.5 years
|
|
Respiratory, thoracic and mediastinal disorders
Hoarseness
|
11.8%
2/17 • About 3.5 years
|
|
Respiratory, thoracic and mediastinal disorders
Laryngeal mucositis
|
5.9%
1/17 • About 3.5 years
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
5.9%
1/17 • About 3.5 years
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
5.9%
1/17 • About 3.5 years
|
|
Respiratory, thoracic and mediastinal disorders
Postnasal drip
|
5.9%
1/17 • About 3.5 years
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
5.9%
1/17 • About 3.5 years
|
|
Respiratory, thoracic and mediastinal disorders
Sore throat
|
5.9%
1/17 • About 3.5 years
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
5.9%
1/17 • About 3.5 years
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
11.8%
2/17 • About 3.5 years
|
|
Skin and subcutaneous tissue disorders
Hair color change
|
5.9%
1/17 • About 3.5 years
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
11.8%
2/17 • About 3.5 years
|
|
Skin and subcutaneous tissue disorders
Nail changes
|
5.9%
1/17 • About 3.5 years
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
17.6%
3/17 • About 3.5 years
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
17.6%
3/17 • About 3.5 years
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
5.9%
1/17 • About 3.5 years
|
|
Vascular disorders
Hypertension
|
35.3%
6/17 • About 3.5 years
|
|
Vascular disorders
Hypotension
|
11.8%
2/17 • About 3.5 years
|
|
Gastrointestinal disorders
Ascites
|
11.8%
2/17 • About 3.5 years
|
|
Gastrointestinal disorders
Bloating
|
11.8%
2/17 • About 3.5 years
|
|
Gastrointestinal disorders
Constipation
|
29.4%
5/17 • About 3.5 years
|
|
Gastrointestinal disorders
Diarrhea
|
52.9%
9/17 • About 3.5 years
|
|
Gastrointestinal disorders
Dry mouth
|
11.8%
2/17 • About 3.5 years
|
|
Gastrointestinal disorders
Dyspepsia
|
5.9%
1/17 • About 3.5 years
|
|
Gastrointestinal disorders
Dysphagia
|
5.9%
1/17 • About 3.5 years
|
|
Gastrointestinal disorders
Flatulence
|
5.9%
1/17 • About 3.5 years
|
|
Gastrointestinal disorders
Hemorrhoids
|
5.9%
1/17 • About 3.5 years
|
|
Gastrointestinal disorders
Mucositis oral
|
23.5%
4/17 • About 3.5 years
|
|
Gastrointestinal disorders
Nausea
|
41.2%
7/17 • About 3.5 years
|
|
Gastrointestinal disorders
Oral hemorrhage
|
5.9%
1/17 • About 3.5 years
|
|
Gastrointestinal disorders
Oral pain
|
11.8%
2/17 • About 3.5 years
|
|
Gastrointestinal disorders
Rectal hemorrhage
|
5.9%
1/17 • About 3.5 years
|
|
Gastrointestinal disorders
Rectal pain
|
5.9%
1/17 • About 3.5 years
|
|
Gastrointestinal disorders
Vomiting
|
23.5%
4/17 • About 3.5 years
|
|
General disorders
Chills
|
17.6%
3/17 • About 3.5 years
|
|
General disorders
Edema limbs
|
29.4%
5/17 • About 3.5 years
|
|
General disorders
Fatigue
|
58.8%
10/17 • About 3.5 years
|
|
General disorders
Fever
|
11.8%
2/17 • About 3.5 years
|
|
General disorders
Flu like symptoms
|
11.8%
2/17 • About 3.5 years
|
|
General disorders
Jaw pain
|
5.9%
1/17 • About 3.5 years
|
|
General disorders
Non-cardiac chest pain
|
11.8%
2/17 • About 3.5 years
|
|
General disorders
Pain
|
17.6%
3/17 • About 3.5 years
|
|
Infections and infestations
Covid-19
|
5.9%
1/17 • About 3.5 years
|
|
Infections and infestations
Gum infection
|
5.9%
1/17 • About 3.5 years
|
|
Injury, poisoning and procedural complications
Bruising
|
17.6%
3/17 • About 3.5 years
|
|
Injury, poisoning and procedural complications
Fall
|
5.9%
1/17 • About 3.5 years
|
|
Injury, poisoning and procedural complications
Fracture
|
5.9%
1/17 • About 3.5 years
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
5.9%
1/17 • About 3.5 years
|
|
Injury, poisoning and procedural complications
Wound complication
|
5.9%
1/17 • About 3.5 years
|
|
Investigations
Activated partial thromboplastin time prolonged
|
5.9%
1/17 • About 3.5 years
|
|
Investigations
Alanine aminotransferase increased
|
64.7%
11/17 • About 3.5 years
|
|
Investigations
Alkaline phosphatase increased
|
35.3%
6/17 • About 3.5 years
|
|
Investigations
Aspartate aminotransferase increased
|
58.8%
10/17 • About 3.5 years
|
|
Investigations
Blood bilirubin increased
|
23.5%
4/17 • About 3.5 years
|
|
Investigations
Blood lactate dehydrogenase increased
|
11.8%
2/17 • About 3.5 years
|
|
Investigations
Creatinine increased
|
23.5%
4/17 • About 3.5 years
|
|
Investigations
Electrocardiogram QT corrected interval prolonged
|
5.9%
1/17 • About 3.5 years
|
|
Investigations
Fibrinogen decreased
|
5.9%
1/17 • About 3.5 years
|
|
Investigations
GGT increased
|
11.8%
2/17 • About 3.5 years
|
|
Investigations
Hemoglobin increased
|
5.9%
1/17 • About 3.5 years
|
|
Investigations
INR increased
|
5.9%
1/17 • About 3.5 years
|
|
Investigations
Lipase increased
|
23.5%
4/17 • About 3.5 years
|
|
Investigations
Lymphocyte count decreased
|
23.5%
4/17 • About 3.5 years
|
|
Investigations
Neutrophil count decreased
|
23.5%
4/17 • About 3.5 years
|
|
Investigations
Platelet count decreased
|
41.2%
7/17 • About 3.5 years
|
|
Investigations
Serum amylase increased
|
11.8%
2/17 • About 3.5 years
|
|
Investigations
Thyroid stimulating hormone increased
|
11.8%
2/17 • About 3.5 years
|
|
Investigations
Weight loss
|
35.3%
6/17 • About 3.5 years
|
|
Investigations
White blood cell decreased
|
35.3%
6/17 • About 3.5 years
|
|
Metabolism and nutrition disorders
Anorexia
|
23.5%
4/17 • About 3.5 years
|
|
Metabolism and nutrition disorders
Dehydration
|
11.8%
2/17 • About 3.5 years
|
|
Metabolism and nutrition disorders
Hypercalcemia
|
5.9%
1/17 • About 3.5 years
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
17.6%
3/17 • About 3.5 years
|
|
Metabolism and nutrition disorders
Hypoalbuminemia
|
52.9%
9/17 • About 3.5 years
|
|
Metabolism and nutrition disorders
Hypocalcemia
|
23.5%
4/17 • About 3.5 years
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
5.9%
1/17 • About 3.5 years
|
|
Metabolism and nutrition disorders
Hypokalemia
|
23.5%
4/17 • About 3.5 years
|
|
Metabolism and nutrition disorders
Hypomagnesemia
|
23.5%
4/17 • About 3.5 years
|
|
Metabolism and nutrition disorders
Hyponatremia
|
47.1%
8/17 • About 3.5 years
|
|
Blood and lymphatic system disorders
Anemia
|
35.3%
6/17 • About 3.5 years
|
|
Cardiac disorders
Sinus bradycardia
|
17.6%
3/17 • About 3.5 years
|
|
Cardiac disorders
Sinus tachycardia
|
5.9%
1/17 • About 3.5 years
|
|
Ear and labyrinth disorders
Hearing impaired
|
5.9%
1/17 • About 3.5 years
|
|
Endocrine disorders
Adrenal insufficiency
|
5.9%
1/17 • About 3.5 years
|
|
Endocrine disorders
Hyperthyroidism
|
17.6%
3/17 • About 3.5 years
|
|
Endocrine disorders
Hypothyroidism
|
29.4%
5/17 • About 3.5 years
|
|
Eye disorders
Dry eye
|
5.9%
1/17 • About 3.5 years
|
|
Eye disorders
Vision Changes
|
5.9%
1/17 • About 3.5 years
|
|
Gastrointestinal disorders
Abdominal distension
|
5.9%
1/17 • About 3.5 years
|
|
Gastrointestinal disorders
Abdominal pain
|
35.3%
6/17 • About 3.5 years
|
|
Gastrointestinal disorders
Anal pain
|
5.9%
1/17 • About 3.5 years
|
Additional Information
Grants Administrative Manager
Johns Hopkins University/SKCCC
Phone: 4439273568
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: LTE60